Solid Biosciences Inc. Tue, Feb 18, 2025, 3:45 AM12 min read In this article: SLDB Solid Biosciences Inc. — Day 90 biopsy data reported from first 3 participants dosed in Phase 1/2 INSPIRE ...

The data showed that VRDN-003 has an extended half-life of 40-50 days, about 4-5 times longer than VRDN-001 and based upon comparisons of publicly disclosed data, significantly longer than other ...

The initial clinical data show that the approach is well-tolerated and provides promising early signals of therapeutic activity with an Objective Response Rate (ORR) of 72.7% (8/11) and a Disease ...

Pharmacokinetics: The pharmacokinetic profile of DF-003 was largely dose proportional and the data support additional clinical trials as a once-daily, orally administered drug.

Solid Biosciences Inc. announced that it will present data from its Phase 1/2 INSPIRE DUCHENNE trial of SGT-003, a gene therapy candidate for Duchenne muscular dystrophy, at the upcoming American ...

“Selection of EB-003 as the lead development candidate from our EVM301 Series is an important inflection point for Enveric, and the updated data highlight its potential to be a novel ...

Announced best-in-disease durability data in BOND-003 Cohort C and promising early signal in Cohort P for cretostimogene grenadenorepvec at the American Urological Association Annual Meeting - - ...

- Positive results show that a single dose of BPL-003, administered adjunctively to SSRIs, produced a rapid and durable antidepressant effect for up to three months after dosing - BPL-003 was well ...

Atai reports positive data for psychedelic drug BPL-003 Jan. 28, 2025 11:54 AM ET Atai Life Sciences N.V. (ATAI) Stock By: Val Brickates Kennedy, SA News Editor 4 Comments ...